Vita Life Sciences (VLS) H1 2025 earnings summary

Executive summary

• Revenue for the half-year ended 30 June 2025 increased by 14% to $45.5 million year-over-year, with profit before income tax up 13% to $6.8 million.

• Achieved strong first half performance with solid fundamentals and strategic investments in brands and markets.

• Broad-based growth was seen across core markets, especially Australia, Malaysia, and Singapore, supported by increased marketing investment.

• Focused on premium complementary medicines across Australia and Southeast Asia, with a mission to provide trusted, effective health solutions.

• A fully franked interim dividend of 4.5 cents per share was declared, up 1.0 cent from the prior corresponding period.

Financial highlights

• Record first half revenue of $45.5M, up 15% year-over-year.

• Net profit for the half-year was $4.8 million, up from $4.3 million in the prior year.

• Gross profit margin increased by 2% to 60%.

• Profit before tax rose 13% to $6.8M compared to the same period last year.

• Cash reserves at $29.4M with no borrowings; equity at $52.6M.

Outlook and guidance

• Momentum expected to continue into the second half, with full year revenue and profit before tax growth targeted over prior year.

• The Board expects momentum in Australia, Malaysia, and Singapore to continue into the second half, with full-year revenue and profit before tax growth anticipated.

• Cautious optimism for China as recent improvements are noted, with further guidance to be provided in Q4.

• Full year guidance to be provided in Q4.